Peripheral blood leukocytes (PBL), namely polymorphonuclear leukocytes (PMNL), are the major carrier of human cytomegalovirus (HCMV) in the blood of immunocompromised patients with HCMV viraemia. By using monoclonal antibodies (MAbs) directed against different early and late viral proteins, we showed that the protein accumulating in PBL, originally reported to be an immediate early (IE) gene product, is the 65K lower matrix early structural protein (ep65). This protein is detectable by immunofluorescence before IE proteins during early stages of the replication cycle of HCMV in permissive human embryonic lung fibroblast cells. However, the appearance ofep65 in the nucleus within 1 h post-infection in the presence of cycloheximide indicates that it represents uptake from the virus inoculum rather than newly synthetized protein. The ep65 MAbs staining PBL did not react with Vero cells infected with a recombinant vaccinia virus encoding the major IE gene (IE1) product, whereas MAbs reactive with the 72K major IE protein stained only faintly a small number of infected PBL. A group of four ep65 MAbs was tested in competitive binding assays to show that ep65 possesses at least three distinct epitopes. These were recognized by all four MAbs in AD169-infected Vero cell cultures when fixed with formaldehyde, whereas only one MAb recognizing a distinct epitope was reactive with methanol-acetone (MA)-fixed AD169-infected Vero cells. In formalin-fixed PBL the number of infected cells stained by the four ep65 MAbs was about twofold that found using MA-fixed cells. Using fluorescenceactivated cell sorter-purified leukocyte subpopulations from viraemic patients with different levels ofviraemia, the ratio of ep65-positive to ep65-negative cells was found to be 1:100 to 1:100000 for PMNL, and only 1:10000 to 1:100000 for mononuclear cells.
Human cytomegalovirus (HCMV) is responsible for severe and often life-threatening infections in immunocompromised patients such as organ transplant recipients (Dummer et al., 1985) and patients with AIDS (Reichert et al., 1983; Fiala et al., 1986) . Systemic HCMV infections are characterized by viraemia often leading to overt organ syndromes in the absence of antiviral treatment. In the last few years, a rapid method of diagnosing HCMV viraemia has been developed, involving the inoculation of peripheral blood leukocytes (PBL) from immunocompromised patients onto monolayers of human fibroblasts, followed by the detection of HCMV immediate early (IE) antigens (lEA) by lEAspecific monoclonal antibodies (MAbs) 16 to 24 h postinfection (p.i.) (Gleaves et al., 1984; Griffiths et al., 1984; Gerna et al., 1990 ). An additional and even more rapid approach to the diagnosis of HCMV infections in blood is the direct detection of HCMV antigens in the nuclei of PBL and, particularly, of peripheral blood polymorphonuclear leukocytes (PMNL) (Van der Bij et aL, 1988a, b; ReveUo et al., 1989a, b) . The HCMV antigen detected in the nuclei of PMNL using a commercially available pool of two MAbs (Clonab CMV; Biotest) has been reported to be an IEA of 70K on the basis of radioimmunoprecipitation (RIP) results (Van der Bij et aL, 1988a, b) .
In this paper, we demonstrate that the nuclear antigen present in PMNL is the early structural protein of 65K (ep65), which is detectable in abundance by indirect immunofluorescence (IFA) within 1 h p.i. in the nuclei of infected cell cultures, before the appearance of the major IE protein of 72K. In this study, several MAbs to the 72K IE protein (p72) were shown to react poorly with PMNL of patients with viraemia.
HCMV reference strain ADI69 was used to infect a mycoplasma-free human embryonic lung fibroblast (HELF) cell strain developed in the laboratory at a multiplicity of 1 to 5. HCMV-infected cells at 24, 48, 72 and 96 h p.i. were used to immunize BALB/c mice on days 0, 21 and 28. Standard techniques were then used to fuse NS1 myeloma cells with spleen cells from immunized animals. Hybridoma supernatants were screened Short communication for HCMV-specific antibodies against both infected and uninfected H E L F cells by IFA and ELISA. Hybridomas producing HCMV-specific antibody were cloned twice by limiting dilution. After collection of ascitic fluids, their immunoglobulin isotype was determined by ELISA (Mouse-Typer subisotyping kit; Bio-Rad) and MAb reactivity was characterized by IFA, ELISA, radioimmunoprecipitation (RIP) and Western blotting (WB) (Gerna et al., 1990) . The specificity of different MAbs used in this study was ascertained by the lack of IFA reactivity with other human herpesviruses [herpes simplex virus (HSV), varicella-zoster virus, EpsteinBarr virus and human herpesvirus 6]. A group of eight MAbs (all IgG1) reactive with a p65 as determined by RIP was selected along with a group of five MAbs reactive with the major IE protein p72 (Fig.  1 a) . However, two subgroups were identified within the MAb group recognizing a p65 : one including four MAbs (4D5, 4C 1, 2A6 and 1 C3) recognizing the early structural protein (ep65 MAbs) detectable prior to D N A replication (Goins & Stinski, 1986) and potentially corresponding to the lower matrix protein described by Roby & Gibson (1986) (see below), and the other including four MAbs (1A2, 2A5, 3D6 and 5B6) reactive with a late structural protein (lp65 MAbs) expressed in the nucleus of infected cells after D N A replication and potentially corresponding to pp67 described by Davis & Huang (1985) . Using an m.o.i, of 1 to 5, the four ep65 MAbs recognized a nuclear protein in 100~o of HCMV-infected cells within 1 h p.i. as determined by both IFA and the immunoperoxidase antibody (IPA) technique. At the same time, MAbs to p72 were not reactive, whereas they appeared to stain the nuclei of about 1 ~ of infected cells 2 h p.i. and markedly to stain 30 to 5 0~ of nuclei 6 h p.i. By decreasing the virus inoculum (m.o.i. 0.01), the number of ep65-expressing cells as well as the staining intensity decreased. The ep65 MAbs were highly reactive against polypeptides from purified preparations of virions and dense bodies when tested by WB (Fig. 1 b) , whereas the p72 MAbs were not reactive at all, thus showing that ep65 is a structural protein.
Standard experiments performed for blocking expression of early proteins by using cycloheximide (100 rtg/ml) treatment for 3 h or 15 h followed by actinomycin D (10 I~g/ml) treatment for 3 h (IE conditions) showed that ep65 is detected under the same conditions that allow expression of p72. However, when cycloheximide was added 1 h prior to virus adsorption and maintained in the medium for 3 to 6 h, ep65 was still detected in the nuclei of infected cells, whereas expression of p72 was abolished, thus suggesting that ep65 is mostly taken up from the virus inoculum.
The study of the time course of the production of the H C M V protein reactive with the ep65 MAbs showed that, following its nuclear appearance 1 h p.i., it persisted in the nuclei of H E L F cells giving, in the presence of cycloheximide, an IFA staining pattern which was more or less unaltered until 24 h p.i. In the absence of cycloheximide, brighter nuclear fluorescence evenly distributed over the entire nuclear area was detectable 6 to 24 h p.i. (Fig. 2a) . Then, ep65 started to appear in the cytoplasm, in which it progressively concentrated until 96 h p.i., with a paranuclear area of maximal concentration ( Fig. 2c and Table 1 ). Appearance of ep65 in the cytoplasm was prevented by treatment of infected cell cultures with D N A inhibitors, such as cytosine-arabinoside (Ara-C) or phosphonoacetic acid. In the presence of D N A inhibitors, the amount of ep65 in the nuclei of infected cells at late times of infection (48 to 96 h) slightly increased in comparison with that at early times, whereas the appearance of lp65 was totally blocked. Clonab C M V gave results identical to those with ep65 MAbs. In contrast, p72 was detected exclusively in the nuclei of infected cells until 96 h p.i. (Fig. 2b and d , and Table 1 ) and the presence of D N A inhibitors did not modify the staining pattern.
Since the four ep65 MAbs gave similar I F A / I P A and R I P patterns, they were tested in IPA competitive binding assays (CBAs) (Gerna et al., 1987) . Results showed that whereas two MAbs (4D5 and 4C1) competed with each other, neither of the remaining two (2A6 and 1C3) competed with any of the other three MAbs. Thus, the four ep65 MAbs appeared to react with three different epitopes of the same protein. In the same CBAs, the five IEA MAbs were also included as controls. As expected, they did not compete with any of the four ep65 MAbs.
Finally, the reactivity of ep65 and p72 MAbs was tested by IFA and IPA on Vero cells infected with either a recombinant vaccinia virus (Borysiewicz et al., 1988) encoding p72 of H C M V (Vacc-IE) or AD169. Table 1 shows that the four ep65 MAbs reacted exclusively with cells infected with AD169 (Fig. 2 f ) , whereas all five p72 MAbs reacted with Vero cells infected with either virus (Fig. 2e and g ). However, when using infected cell substrates fixed with 5~ formaldehyde (Randall & Dinwoodie, 1986) or cold methanol-acetone (1:2) in parallel, the four ep65 MAbs behaved as follows: 4D5 and 4C1, recognizing the same epitope and 1C3 reactive to a different ep65 epitope, reacted only with formaldehyde-and not with methanol-acetone-fixed ceils, whereas 2A6, recognizing a third epitope, reacted with cells treated with either fixative (Table 1) . For comparison, Table 1 shows the reactivity of Clonab CMV, as well as that of a widely used lEA MAb (DuPont), with both types of infected Vero cell and both types of fixation. MAbs to the early p52 protein (the major DNA-binding protein) of HCMV (Revello et al., 1991) weakly stained nuclei of AD169-infected Vero cells, whereas the lp65 MAbs did not react with Vero cells infected with either virus (data not shown).
Subsequently, the different groups of MAbs were tested by both IFA and IPA on cytospin preparations of PMNL and mononuclear leukocytes (MNL) from immunocompromised patients with viraemia. Using multiple cytospin preparations from a number of viraemic patients in parallel, all four ep65 MAbs were found to stain the nuclei of PMNL and MNL comparably to Clonab CMV (Fig. 2h to k) . On the other hand, the six p72 MAbs stained only a few cells very faintly and 1p65 MAbs were very weakly reactive with an even lower number of PMNL. In addition, of 2 x 105 PMNL examined the number stained by the four ep65 MAbs (Revello et al., 1989a, b) was similar, with differences not exceeding twofold (Table 1) . Therefore, we concluded that the protein recognized within the nuclei of infected PMNL is the 65K structural phosphoprotein appearing early in the course of infection of cultured cells (Geballe et at., 1986; Britt & Vugler, 1987) . This viral protein is totally different from the non-structural 72K major IE protein described by Stinski et al. (1983) and previously reported to be expressed in PMNL ( Van der Bij et al., 1988a, b) .
Several reports have confirmed that at least three viral proteins comigrate in the 64K to 69K Mr range. (i) pp64-65, which is encoded by a gene located between map units 0.50 and 0-51 (Clark et al., 1984; Nowak et al., 1984; Britt & Vugler, 1987) , is associated with protein kinase activity and represents the lower matrix protein (Roby & Gibson, 1986) . (ii) pp67 is encoded by a gene located between map units 0.40 and 0-42, and also possesses protein kinase activity (Davis et al., 1984; Davis & Huang, 1985) . (iii) gp65 (Britt & Auger, 1986 ) is an envelope glycoprotein expressed on the surface of infected cells. However, the latter two proteins appear to be translated only following viral DNA replication. Our conclusion that the lower matrix phosphoprotein ep65 is actually the major protein detected in PMNL has been confirmed by the finding that Clonab CMV (showing a reactivity identical to that of our ep65 MAbs) reacts with pp65 expressed in Cos 7 cells transfected with a pp65-Rous sarcoma virus long terminal repeat construct (G. Jahn, S. Schmolke & B. Plachter, data presented at the 16th International Herpesvirus Workshop, 1991).
However, our results suggest that detection of ep65 in the nucleus in the presence of cycloheximide in the very early stages of infection is mostly due to breakdown of input virus, at least until 3 to 6 h p.i. when de novo synthesis occurs. The protein ep65 has been shown to be synthesized at early times in HCMV-infected cells in the presence of DNA inhibitors such as Ara-C (Britt & Vugler, 1987) , although at levels approximately 5% of those produced at late times (Geballe et al., 1986 ). It appears to be identifiable as the 64K to 65K protein described by several authors (Clark et al., 1984; Nowak et al., 1984; Pande et al., 1990; Somogyi et al., 1990) , and shown by Britt & Vugler (1987) to be a delayed early phosphorylated protein. In parallel to a similar structural protein of HSV (Campbell et al., 1984) , it could be considered as a potential regulatory protein initiating and controlling IE gene transcription (Britt & Vugler, 1987) . However, this hypothetical control would be more likely to be done by ep65 derived from a virus or dense body inoculum, as suggested by findings showing that, using the polymerase chain reaction, ep65 mRNA is not detected before 3 to 6 h p.i., whereas p72 mRNA is detected in HCMV-infected cells by 1 h p.i. (G. Gerna et al., unpublished results) .
On the basis of our in vitro findings, the abundant presence of ep65 in infected PMNL from immunocompromised patients may represent in vivo phagocytosis of dense bodies, which contain up to 95~o of ep65 (Irmiere & Gibson, 1983) . However, the detection of p72 in a small number of PMNL and of late HCMV antigens in an even lower number of leukocytes suggests that in PMNL a complete replication cycle can occur. This is in agreement with data reported previously showing a significant correlation between levels of antigenaemia and viraemia (Gerna et al., 1990) , as well as virus recovery from either sonicated PMNL preparations (Wunderli et al., 1989; G. Gerna et al., unpublished results) or whole PMNL inoculated onto HELF cells maintained in the presence of DNA inhibitors (G. Gerna et aL, unpublished results) .
Finally, it is noteworthy that the same viral ep65 protein was detected by our ep65 MAbs on fluorescenceactivated cell sorter (FACS) purified fractions of human PBL from viraemic patients, i.e. PMNL, monocytes and T lymphocytes. However, in viraemic patients with different levels of viraemia the ratio of ep65-positive to ep65-negative cells was found to be I : I00 to 1 : 100000 for PMNL, and only 1:10000 to 1:100000 for MNL. These data agree with those obtained using different hybridization techniques to detect viral nucleic acids in leukocyte subpopulations (Saltzman et al., 1988; Dankner et al., 1990) .
